Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation
Edinburgh, Scotland, 1 February 2024 – Cumulus Oncology (a biotech creation company) today proudly unveils the inauguration of GIO Therapeutics AG, based in Basel, Switzerland.
- Edinburgh, Scotland, 1 February 2024 – Cumulus Oncology (a biotech creation company) today proudly unveils the inauguration of GIO Therapeutics AG, based in Basel, Switzerland.
- This newly established biotech company specialises in the development of pharmaceuticals targeting G protein-coupled receptors (GPCR).
- Heading GIO Therapeutics is Dr Xavier Leroy who has been appointed as Chief Executive Officer.
- Dr Xavier Leroy, CEO of GIO Therapeutics commented: “While GPCRs are well-known drug targets, their potential in cancer therapeutics is currently underutilised.